Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
2.880
-0.010 (-0.35%)
At close: May 15, 2025, 4:00 PM
2.920
+0.040 (1.39%)
After-hours: May 15, 2025, 7:44 PM EDT
Daré Bioscience Revenue
Daré Bioscience had revenue of $25.43K in the quarter ending March 31, 2025, with 173.35% growth. This brings the company's revenue in the last twelve months to $25.91K, down -99.08% year-over-year. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$25.91K
Revenue Growth
-99.08%
P/S Ratio
983.79
Revenue / Employee
$1,126
Employees
23
Market Cap
25.49M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
DARE News
- 2 days ago - Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update - GlobeNewsWire
- 6 weeks ago - Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 7 weeks ago - Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - GlobeNewsWire
- 3 months ago - Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development - GlobeNewsWire
- 4 months ago - Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript - Seeking Alpha